TRIM59 and metabolic dysfunction-associated steatotic liver disease: In our study, we found that TRIM59 could promote the steatosis and inflammation in NAFLD cell model, and the inhibition of TRIM59 was a promising strategy to ameliorate NAFLD both in vitro and in vivo.